Grade My Investments
HomeFree Stock Grades › INSM

Insmed Incorporated (INSM) Stock Grade

INSM · Healthcare

A+
Grade updated: August 16, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$26.8B
P/E Ratio
Revenue Growth (YoY)
+66.7%
Net Margin
-210.5%
Return on Equity
Dividend Yield
None

About Insmed Incorporated's fundamentals

Insmed is a biotechnology company with a market capitalization of $26.8 billion that is experiencing strong revenue growth of 66.7% year-over-year. However, the company is currently unprofitable, reporting a net loss in its latest annual statement and operating at a net margin of -210.5%, meaning expenses significantly exceed revenues. The company does not pay a dividend, which is typical for growth-stage biotech firms reinvesting capital into research and development. This profile reflects a company prioritizing revenue expansion and product development over current profitability.

Track INSM free — no credit card required. Live grade + monthly AI report →